Skin cancer in solid organ transplant recipients

OTR; transplant dermatology; immunosuppression-associated skin cancer

Solid organ transplant recipients (OTRs) are the highest-risk population in skin oncology. Published cohorts commonly report cSCC incidence roughly 65–250× higher than in the general population in renal transplant recipients, and around 100× in cardiac / lung recipients, varying by organ, geography, immunosuppression and time from transplant. Tumours behave more aggressively, and cSCC can outpace BCC in long-term renal transplant recipients. Coordinated transplant-dermatology services, field therapy and immunosuppression optimisation reduce long-term morbidity and mortality.

CurrentLast reviewed 20 March 2026

Key points

cSCC outnumbers BCC 4:1 in long-term renal transplant recipients (vs ~1:4 ratio in the general population).

Risk is driven by immunosuppression intensity and duration plus cumulative UV exposure pre- and post-transplant.

Voriconazole (used for fungal prophylaxis in lung transplants) is a recognised cSCC accelerant — minimise duration where alternatives exist.

mTOR inhibitor conversion (sirolimus, everolimus) reduces post-conversion cSCC incidence — coordinate with the transplant team.

Acitretin chemoprophylaxis (0.2–0.5 mg/kg/day) reduces cSCC burden in patients with multiple cSCCs.

Dedicated transplant dermatology clinics reduce long-term skin cancer morbidity (multiple cohort studies).

Immune checkpoint inhibitors carry significant graft-rejection risk — use only with multidisciplinary transplant team consensus.

Risk and disease burden

Standardised incidence ratios (SIR) for cSCC in solid organ transplant recipients vary by transplant type:

Transplant	cSCC SIR	BCC SIR	Melanoma SIR	Kaposi SIR
Renal	65–250	5–10	1.6–3	~50–200 (population-dependent)
Cardiac / lung	~100	~6	~3	~50
Hepatic	~30	~3	~2	~15

Risk increases with time since transplantation and is highest in patients with prior skin cancer or extensive actinic damage at transplant.

Surveillance

Pre-transplant counselling: sun protection, identification of high-risk patients (Fitzpatrick I–II, prior NMSC).
Annual whole-skin examination from transplant onwards by trained clinician.
After a skin cancer: apply the relevant tumour-specific schedule (for example BAD cSCC risk-tiered follow-up) and keep high-risk OTRs under lifelong whole-skin surveillance at an MDT / transplant-dermatology agreed interval.
Patient education and self-examination training; partner-assisted skin checks.

Prevention

Photoprotection

Daily broad-spectrum SPF 30+ to all exposed sites.
Sun-protective clothing, wide-brim hat.
Avoid sunbeds entirely.

Field therapy for actinic damage

Topical 5-FU 5% — established efficacy in OTRs.
Imiquimod 5% — caution as can trigger graft inflammation; lower-strength regimens preferred.
MAL-PDT — well-tolerated, repeatable.

Chemoprevention

Acitretin 0.2–0.5 mg/kg/day reduces cSCC incidence in high-burden patients (RCT evidence). Discontinue gradually — rebound occurs on cessation.
Nicotinamide 500 mg bd reduces NMSC in high-risk non-OTR populations (ONTRAC); evidence weaker in OTRs but considered safe.

Immunosuppression optimisation

mTOR inhibitor conversion (sirolimus or everolimus replacing CNI) — randomised evidence of cSCC reduction; coordinate with transplant nephrology / hepatology.
Reduce overall immunosuppression where graft function permits.
Minimise voriconazole; switch to posaconazole or isavuconazole if anti-fungal cover required.

Management of established skin cancer

Guideline UK national guidance Trial randomised trial NICE TA NICE Technology Appraisal Consensus expert opinion Local MDT MDT-dependent Full key →

OTRs warrant lower thresholds for excision and higher-margin surgery:

Consensus All cSCC in OTRs is high-risk; consider 6 mm margin or Mohs by default.
Guideline BCC: standard margins; high vigilance for new primary BCCs.
Local MDT Melanoma: standard staging and surgical management; SLNB considered as in non-OTRs.
Local MDT Kaposi sarcoma: see Kaposi monograph — strongly consider mTOR conversion.

ImportantImmune checkpoint inhibitors

Cemiplimab, pembrolizumab and other checkpoint inhibitors carry significant graft-rejection risk in OTRs (10–40% in case series). Use only after multidisciplinary discussion with the transplant team, written informed consent and contingency plan for organ-loss scenarios.

UK services

Most UK regions now have dedicated transplant dermatology clinics — joint reviews with transplant teams, pre-transplant skin assessment, and rapid access for new lesions. The British Society for Dermatological Surgery and BAD have published service standards. Referral pathways usually run through the regional transplant centre.

References

Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol; 2002;47:1–17. (Foundational; updated repeatedly.)

Hofbauer GFL et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly; 2009.

Knoll GA et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis. BMJ; 2014;349:g6679.

Bavinck JN et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy. J Clin Oncol; 1995;13:1933–8.